NCT03716856 is a Phase 1 clinical trial of CAR-BCMA T cells in Refractory or Relapsed Multiple Myeloma, sponsored by First Affiliated Hospital of Zhejiang University.

Who is sponsoring NCT03716856?

NCT03716856 is sponsored by First Affiliated Hospital of Zhejiang University.

What drugs are being tested in NCT03716856?

Interventions in NCT03716856: CAR-BCMA T cells, Fludarabine, Cyclophosphamide.

What condition does NCT03716856 study?

NCT03716856 studies Refractory or Relapsed Multiple Myeloma.

Is NCT03716856 still recruiting?

NCT03716856 is currently status unknown. Last updated 8 October 2020.

Last reviewed 2020-10-08 · How we verify

NCT03716856

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma

Status unknown Phase 1 Last updated 8 October 2020

What this trial tests

Phase 1 trial testing CAR-BCMA T cells in Refractory or Relapsed Multiple Myeloma in 11 participants. Status unknown.

Timeline

23 March 2018

Primary endpoint
23 June 2020

23 June 2023

Quick facts

Lead sponsor	First Affiliated Hospital of Zhejiang University
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	11
Start date	23 March 2018
Primary completion	23 June 2020
Estimated completion	23 June 2023
Sites	1 location across China

Drugs / interventions tested

CAR-BCMA T cells — full drug profile →
Fludarabine (FLUDARABINE) — full drug profile →
Cyclophosphamide (cyclophosphamide) — full drug profile →

Conditions studied

Refractory or Relapsed Multiple Myeloma — all drugs for Refractory or Relapsed Multiple Myeloma →

Sponsor

First Affiliated Hospital of Zhejiang University

Who can join

Adults 18 to 70, any sex, with Refractory or Relapsed Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A single arm, open-label pilot study is designed to determine the safety, efficacy and cytokinetics of CAR-BCMA T cells in patients with BCMA-positive refractory or relapsed multiple myeloma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology.
Vanmeerbeek I, Sprooten J, De Ruysscher D, Tejpar S, et al · · 2020 · cited 179× · PMID 32002302 · DOI 10.1080/2162402x.2019.1703449
BCMA-targeted immunotherapy for multiple myeloma.
Yu B, Jiang T, Liu D. · · 2020 · cited 165× · PMID 32943087 · DOI 10.1186/s13045-020-00962-7
Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma.
Roex G, Timmers M, Wouters K, Campillo-Davo D, et al · · 2020 · cited 137× · PMID 33272302 · DOI 10.1186/s13045-020-01001-1
Engineering enhanced CAR T-cells for improved cancer therapy.
Milone MC, Xu J, Chen SJ, Collins MA, et al · · 2021 · cited 111× · PMID 34485921 · DOI 10.1038/s43018-021-00241-5
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
Kegyes D, Constantinescu C, Vrancken L, Rasche L, et al · · 2022 · cited 53× · PMID 35672793 · DOI 10.1186/s13045-022-01296-2
Multiple Myeloma Therapy: Emerging Trends and Challenges.
Dima D, Jiang D, Singh DJ, Hasipek M, et al · · 2022 · cited 51× · PMID 36077618 · DOI 10.3390/cancers14174082
Multiple myeloma: signaling pathways and targeted therapy.
Lu Q, Yang D, Li H, Niu T, et al · · 2024 · cited 50× · PMID 38961036 · DOI 10.1186/s43556-024-00188-w
BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma.
Cho SF, Lin L, Xing L, Li Y, et al · · 2020 · cited 42× · PMID 32516895 · DOI 10.3390/cancers12061473

Verify or expand the search:

Other trials of CAR-BCMA T cells

Trials testing the same drug.

NCT03380039 — Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma · NA · unknown

Other recruiting trials for Refractory or Relapsed Multiple Myeloma

Currently open trials in the same condition.

NCT06952478 — A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With · Phase 3 · recruiting

Other First Affiliated Hospital of Zhejiang University trials

Trials by the same sponsor.

NCT07537192 — Inulin-Spirulina Co-intervention for Insomnia Disorder · NA · not yet recruiting
NCT07510867 — 18F-FAPI PET/CT and MRI in Gastric Cancer · not yet recruiting
NCT07589647 — Research on the Efficacy and Safety of Targeted Suprachiasmatic Nucleus Electrical Stimulation for Improving Metabolic D · NA · recruiting
NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
NCT07468162 — Characteristic Electroencephalogram of General Anesthesia · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03716856 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Zhejiang University
Last refreshed: 8 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03716856.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing